Design, synthesis and anti-inflammatory activity study of lansiumamide analogues for treatment of acute lung injury
作者:Liyan Song、Gang Li、Wen Guan、Zhijun Zeng、Yanghui Ou、Tongchao Zhao、Jiayu Li、Dengqin He、Xiangxiang Fang、Yali Zhang、Jia-qiang Wu、Rongbiao Tong、Hongliang Yao
DOI:10.1016/j.biopha.2023.115412
日期:2023.10
Acute lung injury (ALI) is an inflammation-mediated respiratory disease with a high mortality rate. Medications with anti-inflammatory small molecules have been demonstrated in phase I and II clinical trials to considerably reduce the ALI mortality. In this study, two series of lansiumamide analogues were designed, synthesized, and evaluated for anti-inflammatory activity for ALI treatment. We found
急性肺损伤(ALI)是一种炎症介导的呼吸道疾病,死亡率很高。I 期和 II 期临床试验已证明含有抗炎小分子的药物可显着降低 ALI 死亡率。在这项研究中,设计、合成了两个系列的兰硫酰胺类似物,并评估了其治疗 ALI 的抗炎活性。我们发现化合物8n通过抑制LPS诱导的Raw264.7细胞中促炎细胞因子白细胞介素6(IL-6)和白细胞介素1β(IL-1β)的表达并激活Nrf2/HO表现出最佳的抗炎活性。 -1途径。此外,我们在LPS诱导的ALI小鼠模型中发现,化合物8n显着减少炎症细胞向肺组织的浸润,从而达到保护肺组织和改善ALI的效果。此外,我们的小鼠模型研究表明,化合物8n具有良好的祛痰作用。这些结果一致支持兰硫酰胺类似物8n代表了一类新型抗炎药,有潜力作为先导化合物进一步开发为治疗 ALI 的治疗药物。